Aluminum Canisters for Inhalation Aerosols Market to Reach USD 1.31 Billion by 2035 at 5.7% CAGR Amid Rising Metered-Dose Inhaler Demand and Expanding Generic Respiratory Drug Manufacturing

MARKET SYNOPSIS

The global Aluminum Canisters for Inhalation Aerosols market size was USD 748.6 Million in 2025 and is expected to register a revenue CAGR of 5.7% during the forecast period. Demand for aluminum canisters in metered-dose inhalers is increasing owing to the expanding global burden of asthma and chronic obstructive pulmonary disease, which the World Health Organization estimated affected over 550 million people as of 2024. Aluminum is the primary canister material because it is chemically inert, lightweight, and capable of withstanding internal pressure from hydrofluorocarbon propellants. The EMA's extractables and leachables testing requirements under EMA/CHMP/QWP/49313/2015 have reinforced aluminum as the material of choice, as its internal polymer coating profile is validated across hundreds of approved formulations. On 22 January 2025, Presspart Manufacturing Ltd., which is a specialist manufacturer of aluminum canisters for inhaled drug delivery headquartered in Blackburn, United Kingdom, completed a capacity expansion adding two canister forming lines with combined annual output of 120 million units for generic respiratory drug manufacturers. Such additions are expected to support revenue growth of the market over the forecast period.

The market entered the forecast period having gone through a period of formulation transition as manufacturers replaced chlorofluorocarbon propellants with HFA-134a and HFA-227ea alternatives, requiring re-validation of canister coating chemistry. Generic respiratory approvals accelerated after the US FDA published product-specific guidance for albuterol sulfate inhalation aerosol, drawing contract manufacturers into canister procurement at scale. For instance, in September 2024, Recipharm AB, Sweden, announced a multi-year supply agreement covering internally coated 17 mL aluminum canisters for two respiratory generic products, with volumes expected to exceed 40 million units annually by 2026. These are some of the key factors driving revenue growth of the market.

However, aluminium ingot price volatility tied to energy cost fluctuations in primary smelting, as well as the twelve to eighteen months typically required to qualify internal polymer coatings against drug-specific extractables and leachables specifications, are factors that could restrain revenue growth of the market. Qualification timelines limit how quickly canister suppliers can onboard new pharmaceutical customers responding to newly approved generic products. The escalation of the United States-Iran confrontation in late February 2026 and uncertainty through Q1 and Q2 2026 disrupted bauxite and alumina shipments transiting Gulf of Oman routes, directly affecting feedstock availability for canister blank producers in the Middle East and Asia. These factors substantially limit Aluminum Canisters for Inhalation Aerosols market growth over the forecast period.

Request Your Free Sample Report: https://www.emergenresearch.com/request-free-sample/143948

SEGMENT HIGHLIGHTS

Based on canister size, the global Aluminum Canisters for Inhalation Aerosols market is segmented into Below 14 mL, 14 mL to 19 mL, Above 19 mL, and others. The 14 mL to 19 mL segment holds the largest share because this range covers volumes used in the most prescribed MDI products, including bronchodilators and corticosteroid combinations accounting for the highest unit volumes dispensed globally. A 17 mL canister at standard fill weight delivers 200 actuations, matching the dosing schedule preferred by formulators and payors across regulated markets. Pharmaceutical manufacturers have validated formulation and valve combinations against this geometry in hundreds of approved products, creating incumbency that limits switching. The 14 mL to 19 mL segment is expected to register a rapid revenue growth rate in the global Aluminum Canisters for Inhalation Aerosols market over the forecast period.

Based on application, the global Aluminum Canisters for Inhalation Aerosols market is segmented into Respiratory Drug Delivery, Veterinary Inhalation Products, Nasal Drug Delivery, and others. Respiratory drug delivery commands the largest share because asthma and COPD protocols rely on pressurised MDIs as a first-line delivery mechanism across high-income and middle-income markets. Approved dossiers specify the exact canister including coating type, wall thickness, and neck geometry, giving the aluminum canister its own regulatory identity. Expansion of government reimbursement for inhaled therapies across Southeast Asia and Latin America has broadened the patient base for generic MDI manufacturers. The Respiratory Drug Delivery segment is expected to register a rapid revenue growth rate in the global Aluminum Canisters for Inhalation Aerosols market over the forecast period.

Request a Discount on This Report: https://www.emergenresearch.com/request-for-discount/143948

REGIONAL HIGHLIGHTS

Based on regional analysis, the Aluminum Canisters for Inhalation Aerosols market in Europe accounted for largest revenue share in 2025. The European Commission's F-Gas Regulation review has pushed pharmaceutical companies to accelerate HFA propellant transition timelines, sustaining demand for certified aluminum canisters. On 15 March 2025, TUBEX GmbH, which is a German manufacturer of aluminum aerosol packaging and pharmaceutical canisters, completed qualification of a new internal coating at its Gilching facility, receiving EMA extractables and leachables compliance sign-off for HFA-134a-based formulations. The escalation of the United States-Iran confrontation in late February 2026 raised alumina feedstock costs for European producers reliant on Gulf-region supply routes, compressing converter margins through Q2 2026.

Market in North America is expected to register a rapid revenue growth rate over the forecast period. The US FDA's product-specific guidance for generic inhalation aerosols drew more than a dozen contract manufacturers into MDI production since 2022, each requiring validated canister supply agreements. The Inflation Reduction Act's Medicare coverage extensions for asthma and COPD medications expanded the insured patient base for generic inhaler manufacturers. The United States-Iran confrontation escalating in late February 2026 disrupted Gulf-region bauxite and alumina flows, raising procurement costs for North American canister blank producers through Q1 and Q2 2026.

Market in Asia Pacific is expected to register a significantly high revenue growth rate over the forecast period. India's Production Linked Incentive scheme for pharmaceuticals has incentivised domestic MDI manufacturing capacity requiring aluminum canisters at scale. China's National Medical Products Administration accelerated generic inhalation aerosol approvals under its reference-listed drug framework in 2024, broadening the domestic market for canisters and finished MDI products. The United States-Iran confrontation in early 2026 disrupted alumina shipments from Middle Eastern suppliers to Asian manufacturers, raising input costs and extending lead times for canister producers in India and Southeast Asia through mid-2026.

Read the Full Report Description: https://www.emergenresearch.com/industry-report/aluminum-canisters-for-inhalation-aerosols-market

MAJOR COMPANIES IN THE REPORT INCLUDE:

Presspart Manufacturing Ltd.
TUBEX GmbH
Recipharm AB
Nampak Ltd.
Ball Corporation
Bharat Containers
CCL Container (Hermitage)
Ardagh Group S.A.
KRÜGER AEROSOL GmbH
Alucon Public Company Limited

Contact us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +12092086299
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.